Preliminary study of Huai Qi Huang granules delay the development of primary glomerular diseases in human

Figures & data

Table 1. Changes in serum levels of biochemical indexes before and after treatment with Huai Qi Huang granules (, n = 16).

	Indexes
Groups	SMDA (nmol/mL)	SCr (µmol/L)	eGFR (mL/min/1.73 m^2)	SCys-C (mg/L)	SNGAL (µg/L)
Normal subjects	4.08 ± 0.80	81.71 ± 8.76	106.90 ± 4.84	0.68 ± 0.14	44.53 ± 6.32
Treatment subjects	–	–	–	–	–
Baseline	9.56 ± 1.25*	123.12 ± 35.57*	66.88 ± 16.72*	1.15 ± 0.28*	364.10 ± 66.71*
Day 30	8.54 ± 1.41^a	115.20 ± 32.74^b	71.95 ± 18.27^b	1.07 ± 0.28^b	324.71 ± 61.47^a
Day 90	6.39 ± 1.18^a,c	110.97 ± 32.16^a	74.98 ± 19.10^a	0.98 ± 0.30^a,d	277.19 ± 58.60^a,c

Notes: SMDA, serum malondialdehyde; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; SCys-C, serum cystatin C; SNGAL, serum neutrophil gelatinase-associated lipocalin.

*p < 0.01, compared with normal control.

^ap < 0.01, ^bp < 0.05; compared with base values.

^cp < 0.01, ^dp < 0.05; compared Day 30 after treatment.

Table 2. Effects of HQH granules on urinary markers of renal injury before and after treatment with Huai Qi Huang granules (, n = 16).

	Indexes
Groups	UNGAL (μg/g)	UCys-C (μg/g)	UAlb (mg/g)	UTP (mg/g)	Erythrocyte count
Normal subjects	9.51 ± 2.48	4.74 ± 0.74	23.67 ± 8.10	129.18 ± 32.29	0.30 ± 0.10
Treatment subjects	–	–	–	–	–
Baseline	93.37 ± 39.65*	7.118 ± 2.66*	386.03 ± 124.56*	638.06 ± 219.63*	8.74 ± 3.81*
Day 30	57.43 ± 19.62^a	4.46 ± 1.51^a	210.95 ± 84.99^a	345.24 ± 133.51^a	5.26 ± 3.15^a
Day 90	43.85 ± 19.83^a,b	3.29 ± 0.89^a,b	166.67 ± 68.36^a,b	264.91 ± 102.12^a,c	2.58 ± 1.58^a,b

Notes: UNGAL, urinary neutrophil gelatinase-associated lipocalin; UCys-C, urinary cystatin C; UAlb, urinary albumin; UTP, urinary total protein.

*p < 0.01, compared with normal control subjects.

^ap < 0.01, compared with base values.

^bp < 0.01, ^cp < 0.05; compared with Day 30 after treatment.